European Journal of Cancer
Volume 46, Issue 8 , Pages 1445-1455, May 2010

Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells

  • Amélie Rebillard

      Affiliations

    • EA 4427 SeRAIC, Faculty of Pharmacy, University of Rennes 1, IFR 140 GFAS, Rennes F-35043, France
    • New address: Laboratoire Physiologie M2S, UFR-APS, Université de Rennes 2, Campus La Harpe, Avenue Charles Tillon, Rennes F-35044, France.
  • ,
  • Sandrine Jouan-Lanhouet

      Affiliations

    • EA 4427 SeRAIC, Faculty of Pharmacy, University of Rennes 1, IFR 140 GFAS, Rennes F-35043, France
  • ,
  • Elodie Jouan

      Affiliations

    • EA 4427 SeRAIC, Faculty of Pharmacy, University of Rennes 1, IFR 140 GFAS, Rennes F-35043, France
  • ,
  • Patrick Legembre

      Affiliations

    • EA 4427 SeRAIC, Faculty of Pharmacy, University of Rennes 1, IFR 140 GFAS, Rennes F-35043, France
  • ,
  • Mathieu Pizon

      Affiliations

    • CNRS UMR 5164, University of Bordeaux 2, Bordeaux F-33076, France
  • ,
  • Odile Sergent

      Affiliations

    • EA 4427 SeRAIC, Faculty of Pharmacy, University of Rennes 1, IFR 140 GFAS, Rennes F-35043, France
  • ,
  • David Gilot

      Affiliations

    • EA 4427 SeRAIC, Faculty of Pharmacy, University of Rennes 1, IFR 140 GFAS, Rennes F-35043, France
  • ,
  • Xavier Tekpli

      Affiliations

    • EA 4427 SeRAIC, Faculty of Pharmacy, University of Rennes 1, IFR 140 GFAS, Rennes F-35043, France
  • ,
  • Dominique Lagadic-Gossmann

      Affiliations

    • EA 4427 SeRAIC, Faculty of Pharmacy, University of Rennes 1, IFR 140 GFAS, Rennes F-35043, France
  • ,
  • Marie-Thérèse Dimanche-Boitrel

      Affiliations

    • EA 4427 SeRAIC, Faculty of Pharmacy, University of Rennes 1, IFR 140 GFAS, Rennes F-35043, France
    • Corresponding Author InformationCorresponding author: Address: EA 4427 SeRAIC, Université de Rennes 1, Faculté de Pharmacie, 2 Av du Pr Léon Bernard, Rennes F-35043, France. Tel.: +33 223234837; fax: +33 223234794.

Received 23 October 2009; received in revised form 20 January 2010; accepted 26 January 2010. published online 08 March 2010.

Abstract 

In human colon cancer cells, cisplatin-induced apoptosis involves the Fas death receptor pathway independent of Fas ligand. The present study explores the role of ezrin and actin cytoskeleton in relation with Fas receptor in this cell death pathway. In response to cisplatin treatment, a rapid and transient actin reorganisation is observed at the cell membrane by fluorescence microscopy after Phalloidin-FITC staining. This event is dependent on the membrane fluidification studied by electron paramagnetic resonance and necessary for apoptosis induction. Moreover, early after the onset of cisplatin treatment, ezrin co-localised with Fas at the cell membrane was visualised by membrane microscopy and was redistributed with Fas, FADD and procaspase-8 into membrane lipid rafts as shown on Western blots. In fact, cisplatin exposure results in an early small GTPase RhoA activation demonstrated by RhoA–GTP pull down, Rho kinase (ROCK)-dependent ezrin phosphorylation and actin microfilaments remodelling. Pretreatment with latrunculin A, an inhibitor of actin polymerisation, or specific extinction of ezrin or ROCK by RNA interference prevents both cisplatin-induced actin reorganisation and apoptosis. Interestingly, specific extinction of Fas receptor by RNA interference abrogates cisplatin-induced ROCK-dependent ezrin phosphorylation, actin reorganisation and apoptosis suggesting that Fas is a key regulator of cisplatin-induced actin remodelling and is indispensable for apoptosis. Thus, these findings show for the first time that phosphorylation of ezrin by ROCK via Fas receptor is involved in the early steps of cisplatin-induced apoptosis.

Keywords: Cisplatin, Fas, RhoA–GTP, ROCK, Ezrin, Actin cytoskeleton, Membrane fluidity, Colon cancer, Lipid rafts, RNA interference

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0959-8049(10)00082-1

doi:10.1016/j.ejca.2010.01.034

European Journal of Cancer
Volume 46, Issue 8 , Pages 1445-1455, May 2010